Prescription Drugs

Medicare Will Cover Weight-Loss GLP-1 Drugs for $50/Month Starting July 2026

A new Medicare demonstration — the GLP-1 Bridge — lets eligible Part D members get Wegovy and Zepbound for weight loss at $50 a month, from July 1, 2026 through December 31, 2027.

For years, the short answer to “Does Medicare cover weight-loss drugs?” was simply no. That’s changing — at least temporarily. Starting July 1, 2026, Medicare is launching a short-term demonstration called the Medicare GLP-1 Bridge that lets eligible Part D members get certain GLP-1 medications for weight loss at a predictable $50 per month. The program runs through December 31, 2027.

This is one of the few Medicare changes that ordinary beneficiaries immediately understand and care about — it involves widely used drugs like Wegovy® and Zepbound®, and it changes a long-standing answer.

What you’ll pay

Eligible beneficiaries pay $50 for a one-month supply. Behind the scenes, participating manufacturers provide the drugs at a net price of about $245 per month, and the demonstration covers the difference — so your out-of-pocket cost stays at that flat $50.

Which drugs are included

The Bridge covers these medications when used to reduce excess body weight and keep it off:

  • Foundayo® — all formulations
  • Wegovy® — all formulations (injection and tablets)
  • Zepbound® — the KwikPen® formulation

Note that Ozempic® is not included. Ozempic remains covered under regular Part D when prescribed for type 2 diabetes, not for weight loss.

Who qualifies

To be eligible, you must be enrolled in a Medicare Part D plan, be 18 or older, and meet one of these clinical criteria at the time you start therapy:

  • A BMI of 35 or higher, or
  • A BMI of 27 or higher plus a diagnosis of pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease

The drug must be prescribed for weight reduction alongside lifestyle changes (structured nutrition and physical activity), consistent with the FDA-approved label.

How to get it: prior authorization is required

This isn’t automatic. Your prescriber must submit a prior authorization request confirming you meet the criteria. The Bridge runs outside the normal Part D benefit — in 2026, CMS uses a single central processor to handle approvals, claims, and pharmacy payment — so it works a little differently from a typical Part D prescription.

What to do next

If you or a loved one might qualify, the first step is a conversation with your prescriber about whether one of these medications is appropriate. From there, we can help with the Medicare side: compare Medicare Part D plans to make sure yours and your pharmacy are set up correctly, learn about ways to lower your Medicare prescription drug costs, and check whether a Medicare Advantage plan that includes prescription drug coverage fits your needs.

Have questions about Medicare drug coverage? Contact AltaMedicare — Bret Swope is a licensed Utah Medicare agent, and the consultation is free with no pressure. You can also read our plain-English guides on whether Medicare covers Wegovy and whether Medicare covers Zepbound.

This article is general education, not medical advice or a guarantee of coverage. Eligibility, covered drugs, and costs are set by Medicare and can change. Always confirm current details with your plan, your prescriber, or a licensed agent.

Source: Based on information from cms.gov. Coverage details depend on your specific plan and can change — always confirm with your plan or a licensed agent.

Frequently Asked Questions

Does Medicare cover Wegovy now?

Through the Medicare GLP-1 Bridge, eligible Part D members can get Wegovy for weight reduction at $50 per month from July 1, 2026 through December 31, 2027. Outside this demonstration, Medicare generally still does not cover GLP-1 drugs for weight loss alone, though some plans may cover them for an FDA-approved use such as reducing cardiovascular risk.

Does Medicare cover Ozempic for weight loss?

No. Ozempic is not included in the Medicare GLP-1 Bridge. The program currently includes Foundayo®, Wegovy®, and the Zepbound® KwikPen. Ozempic is approved to treat type 2 diabetes — not weight loss — and is covered under normal Part D for that use, but it is not part of this demonstration.

Who qualifies for the GLP-1 Bridge?

You must be enrolled in a Medicare Part D plan, be at least 18, and either have a BMI of 35 or higher, or a BMI of 27 or higher plus a diagnosis of pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. The drug must be prescribed for weight reduction along with lifestyle changes, and your provider must submit a prior authorization confirming you meet the criteria.

Which drugs are included?

All formulations of Foundayo, all formulations of Wegovy (injection and tablets), and the KwikPen formulation of Zepbound — when used to reduce excess body weight and maintain weight reduction.

Is prior authorization required?

Yes. Your prescriber must submit a prior authorization request attesting that you meet the clinical criteria before you can get the medication through the Bridge.

Is this part of Medicare Part D?

You need to be enrolled in Part D to participate, but the GLP-1 Bridge operates outside the normal Part D benefit and payment flow as a separate, temporary demonstration. In 2026, CMS uses a single central processor to handle prior authorization, claims, and pharmacy payment.

Want a real person to walk through this with you?

Bret Swope is a licensed Utah Medicare agent. No bots, no pressure — just clear answers.